Pharmaceuticals
Sequins™ Announces Availability of First Products - Bolsters Team for Commercialization
SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and Whole Genome Sequencing Core Control Sets, along with an ...
2025-02-05 00:00
2092
GC Labs strengthens global ties and explores new opportunities at Medlab Middle East 2025
YONGIN, South Korea, Feb. 4, 2025 /PRNewswire/ -- GC Labs, a leading clinical
laboratory inSouth Korea, announced the successful completion of the second day
of the Medlab Middle East 2025, which is being held at theDubai World Trade
Centre (DWTC), UAE betweenFebruary 3-6.
2025-02-04 14:56
2569
China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth
HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has...
2025-02-03 21:00
4213
Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery
CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), announced today that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), aBoston-based animal biotechnology company...
2025-02-03 20:00
2394
CStone Partners with SteinCares to Market Sugemalimab in Latin America
* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. * This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals...
2025-01-27 12:30
3076
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...
2025-01-27 09:53
2901
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor
2025-01-24 22:00
5048
Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention
SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference inSan Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures. The Jones...
2025-01-24 14:59
3255
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxali...
2025-01-23 08:31
2503
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation
2025-01-22 21:00
3343
L&C Bio Secures World's First NMPA Approval for 'MegaDerm Plus' in China
SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ -- L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval fromChina's National Medical Products Administration (NMPA) for its acellular dermal ma...
2025-01-22 20:30
3096
Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
* Recorded Q4'24 consolidated revenue of KRW 1.26 trillion * Recorded FY'24 consolidated revenue of KRW 4.55 trillion * Poised for further growth with expanded capacity and new service offerings INCHEON,South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a globa...
2025-01-22 15:06
2688
Akeso Received Payment for the Development Collaboration on Tagitanlimab
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclona...
2025-01-22 14:57
3569
Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held ...
2025-01-22 14:43
2674
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON, Jan. 21, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advance...
2025-01-22 11:01
2470
TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions and alignment with the U.S. Food and Drug Admin...
2025-01-21 15:30
2378
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...
2025-01-21 10:34
2941
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®）has received marketing authorizatio...
2025-01-17 10:56
2559
LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference
* New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" * Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing * Incheon Songdo Bio Campus Plant 1 Un...
2025-01-17 07:11
3515
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the closing o...
2025-01-17 03:10
4023
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
6681
